Redeye adjusts its fair value range following the announcement of the rights issue.
Stabila utdelningar eller fallande trend? Redeye tittar närmare på bolagets utdelningar.
* Sales -5%, adj. EBIT SEK -2m vs. ABGSCe * Seasonal effects impacted Aesthetics segment * Recycling...
Q4 results were broadly in line with expectations, though regional performance diverged from our for...
Sales -18% vs. ABGSCe, EBIT SEK 11m vs. ABGSCe 16m* Newbuild market down 50% y-o-y, affecting growth...
Redeye considers I-Tech’s Q3 figures relatively soft, missing our top-line estimate by 10% and EBITD...
Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc.
Redeye expects another quarter with high activity in terms of deliveries and reported sales.
Redeye updates its estimates and valuation after Vitec’s Q3 2025 report.
Organic growth could return in Q3 y/y after being negative for the past seven quarters.
Redeye retains its positive view of Carasent following the Q3 report.
Plejd rapporterade ett starkt tredje kvartal med en nettoomsättning på 215,3 MSEK (153,1), motsvaran...
Redeye shares its preview of BONESUPPORT’s Q3 2025 results, due October 23.
Redeye provides its initial take on OEM’s Q3 2025 report, which aligned with our top-line estimate a...
Redeye shares its preview of Xvivo’s Q3 2025 results, due October 23.
Redeye leaves a comment following Alzinova’s announcement of a SEK11m short-term loan aimed at secur...
Duell’s Q4 results were mixed, with the Nordics outperforming expectations while Central Europe fell...
Redeye is encouraged by GomSpace's upgraded guidance published last night, raising mid range revenue...
Redeye comments on Waystream’s Q3 report, which showed solid double-digit organic growth coupled wit...
Redeye provides its initial take on Vitec’s Q3 2025 report, which came in broadly below our estimate...
